Bio-Technology General announces approval of human growth hormone in Brazil.ISELIN, N.J.--(BUSINESS WIRE)--Oct. 8, 1996-- -- Largest market for growth hormone growth hormone or somatotropin (sōmăt'ətrō`pən), glycoprotein hormone released by the anterior pituitary gland that is necessary for normal skeletal growth in humans (see protein). in Latin America -- Bio-Technology General Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTGC BTGC Bio-Technology General (stock symbol) BTGC Bukit Tinggi Golf Club (Malaysia) ) today announced its human growth hormone human growth hormone (HGH): see growth hormone. , Bio-Tropin, has received marketing approval from the Brazilian Ministry of Health. The product, which is expected to be launched within the coming months, will be marketed by Laboratorio Enila. The Brazilian market for human growth hormone is larger than that of any other human growth hormone market in Latin America. BTG's human growth hormone is now marketed in nineteen countries around the world. As announced last year, the Company is prevented from marketing its product in the United States at this time due to a preliminary injunction A temporary order made by a court at the request of one party that prevents the other party from pursuing a particular course of conduct until the conclusion of a trial on the merits. A preliminary injunction is regarded as extraordinary relief. issued in August 1995. The decision yesterday by the Supreme Court declining to hear the case was not unexpected. The Company has previously stated that because of the injunction it has no expectation of generating sales of growth hormone in the U.S. in the coming few years. Through the first six months of 1996, the Company reported worldwide product sales of $19.3 million of which $11.9 million were derived from human growth hormone. Bio-Technology General Corp. develops, manufactures and markets genetically engineered genetically engineered adjective Recombinant, see there and other products for human healthcare. CONTACT: Bio-Technology General Corp. Leah Berkovits, 908/632-8800 or Strategic Growth International Don Weinberger, 516/829-7111 Investor Relations |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion